CA3004150A1 - Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneity - Google Patents
Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneity Download PDFInfo
- Publication number
- CA3004150A1 CA3004150A1 CA3004150A CA3004150A CA3004150A1 CA 3004150 A1 CA3004150 A1 CA 3004150A1 CA 3004150 A CA3004150 A CA 3004150A CA 3004150 A CA3004150 A CA 3004150A CA 3004150 A1 CA3004150 A1 CA 3004150A1
- Authority
- CA
- Canada
- Prior art keywords
- ctcs
- cancer
- cells
- blood
- genomic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6841—In situ hybridisation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70589—CD45
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562250422P | 2015-11-03 | 2015-11-03 | |
| US62/250,422 | 2015-11-03 | ||
| PCT/US2016/059877 WO2017079139A1 (en) | 2015-11-03 | 2016-11-01 | Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3004150A1 true CA3004150A1 (en) | 2017-05-11 |
Family
ID=58662599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3004150A Pending CA3004150A1 (en) | 2015-11-03 | 2016-11-01 | Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneity |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20180321247A1 (https=) |
| EP (1) | EP3371327B1 (https=) |
| JP (1) | JP7043412B2 (https=) |
| CN (2) | CN115341033A (https=) |
| AU (2) | AU2016348401A1 (https=) |
| CA (1) | CA3004150A1 (https=) |
| EA (1) | EA201891085A1 (https=) |
| IL (1) | IL259093A (https=) |
| WO (1) | WO2017079139A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3045918B1 (en) | 2009-10-21 | 2017-12-06 | The Scripps Research Institute | Method of using non-rare cells to detect rare cells |
| EA201691496A1 (ru) | 2014-01-27 | 2016-12-30 | Эпик Сайенсиз, Инк. | Диагностика биомаркеров рака предстательной железы с помощью циркулирующих опухолевых клеток |
| EA201691682A1 (ru) | 2014-02-21 | 2017-02-28 | Эпик Сайенсиз, Инк. | Способы анализирования редких циркулирующих в крови клеток |
| EP3948294B1 (en) * | 2019-03-28 | 2023-06-07 | Lundoch Diagnostics AB | Use of follistatin in type 2 diabetes risk prediction |
| US12412272B2 (en) | 2019-11-26 | 2025-09-09 | University Of Cincinnati | Characterizing intra-site tumor heterogeneity |
| CN117497044A (zh) * | 2022-03-09 | 2024-02-02 | 复旦大学 | 基于单细胞基因组拷贝数变异谱在制造细胞良恶性诊断试剂或检测试剂中的应用 |
| WO2024192141A1 (en) | 2023-03-13 | 2024-09-19 | Dana-Farber Cancer Institute, Inc. | Treatment of cancers having a drug-resistant mesenchymal cell state |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9671405B2 (en) * | 2012-09-19 | 2017-06-06 | Cornell University | Identifying taxane sensitivity in prostate cancer patients |
| DK2981624T3 (da) * | 2013-04-05 | 2020-03-02 | Myriad Genetics Inc | Fremgangsmåder til vurdering af homolog rekombinationsdeficiens og forudsigelse af respons på cancerbehandling |
| US20160266127A1 (en) | 2013-09-30 | 2016-09-15 | Peter Kuhn | Genotypic and Phenotypic Analysis of Circulating Tumor Cells to Monitor Tumor Evolution in Prostate Cancer Patients |
| WO2015073896A2 (en) * | 2013-11-15 | 2015-05-21 | Psma Development Company, Llc | Biomarkers for psma targeted therapy for prostate cancer |
| CA2937051A1 (en) * | 2014-01-17 | 2015-07-23 | Ontario Institute For Cancer Research (Oicr) | Biopsy-driven genomic signature for prostate cancer prognosis |
| EA201691496A1 (ru) * | 2014-01-27 | 2016-12-30 | Эпик Сайенсиз, Инк. | Диагностика биомаркеров рака предстательной железы с помощью циркулирующих опухолевых клеток |
| EP3100052B1 (en) * | 2014-01-30 | 2021-03-10 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for biomarkers predictive of resistance to androgen receptor (ar) targeted therapies |
-
2016
- 2016-11-01 WO PCT/US2016/059877 patent/WO2017079139A1/en not_active Ceased
- 2016-11-01 CN CN202210906018.2A patent/CN115341033A/zh active Pending
- 2016-11-01 EP EP16862785.9A patent/EP3371327B1/en active Active
- 2016-11-01 AU AU2016348401A patent/AU2016348401A1/en not_active Abandoned
- 2016-11-01 JP JP2018543010A patent/JP7043412B2/ja active Active
- 2016-11-01 US US15/773,154 patent/US20180321247A1/en not_active Abandoned
- 2016-11-01 EA EA201891085A patent/EA201891085A1/ru unknown
- 2016-11-01 CN CN201680078293.2A patent/CN108603233A/zh active Pending
- 2016-11-01 CA CA3004150A patent/CA3004150A1/en active Pending
-
2018
- 2018-05-02 IL IL259093A patent/IL259093A/en unknown
-
2021
- 2021-01-06 US US17/142,767 patent/US20210405055A1/en not_active Abandoned
-
2023
- 2023-01-24 AU AU2023200364A patent/AU2023200364A1/en not_active Abandoned
-
2024
- 2024-07-11 US US18/770,366 patent/US20250180564A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3371327A4 (en) | 2019-07-03 |
| US20250180564A1 (en) | 2025-06-05 |
| WO2017079139A1 (en) | 2017-05-11 |
| EA201891085A1 (ru) | 2018-11-30 |
| US20180321247A1 (en) | 2018-11-08 |
| AU2023200364A1 (en) | 2023-02-23 |
| EP3371327B1 (en) | 2024-12-18 |
| IL259093A (en) | 2018-06-28 |
| CN115341033A (zh) | 2022-11-15 |
| JP2018534595A (ja) | 2018-11-22 |
| EP3371327A1 (en) | 2018-09-12 |
| AU2016348401A1 (en) | 2018-05-24 |
| US20210405055A1 (en) | 2021-12-30 |
| JP7043412B2 (ja) | 2022-03-29 |
| CN108603233A (zh) | 2018-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220390451A1 (en) | Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneity | |
| US20240103003A1 (en) | Detection of prostate specific membrane antigen (psma) expression on circulating tumor cells (ctc) | |
| US20250155440A1 (en) | Methods of determining therapies based on single cell characterization of circulating tumor cells (ctcs) in metastatic disease | |
| US20250180564A1 (en) | Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneity | |
| US20230033449A1 (en) | Circulating tumor cell diagnostics for detection of neuroendocrine prostate cancer (nepc) | |
| US20200333345A1 (en) | Circulating tumor cell diagnostics for prostate cancer biomarkers | |
| US20170242016A1 (en) | Circulating tumor cell diagnostics for therapy targeting pd-l1 | |
| EP3100052A1 (en) | Circulating tumor cell diagnostics for biomarkers predictive of resistance to androgen receptor (ar) targeted therapies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20211101 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250912 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20251113 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260107 |